```html

Wegener’s Rhinosinusitis (Granulomatosis with Polyangiitis–Related Sinus Disease)

Overview

Wegener’s rhinosinusitis is chronic inflammation of the nasal passages and sinuses that occurs as part of granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis. GPA is a rare autoimmune vasculitis that attacks small‑ and medium‑sized blood vessels, most often affecting the respiratory tract (nose, sinuses, lungs) and kidneys.

While GPA affects men and women equally, the disease typically presents in adults aged 40–60 years. The overall incidence of GPA in the United States is about 3 cases per million people per year (CDC, 2023). Approximately 70‑80 % of patients develop upper‑airway involvement, and sinus disease is one of the earliest and most common manifestations. When sinus inflammation is the predominant feature, clinicians often refer to it as “Wegener’s rhinosinusitis.”

Symptoms

Symptoms can be subtle at first and may mimic ordinary sinusitis, which can delay diagnosis. Common features include:

• Nasal congestion or obstruction – a feeling of blockage on one or both sides.
• Purulent or bloody nasal discharge – thick, yellow‑green or blood‑streaked mucus.
• Facial pain/pressure – often localized over the cheekbones or forehead.
• Post‑nasal drip – mucus draining down the throat, causing throat irritation.
• Hyposmia or anosmia – reduced or loss of sense of smell.
• Septal perforation – a hole in the nasal septum, leading to crusting and whistling.
• Recurring nosebleeds (epistaxis) – especially when crusts are removed.
• Ulcerative lesions – painful sores on the nasal vestibule or palate.
• Otitis media or hearing loss – middle‑ear effusion caused by eustachian‑tube dysfunction.
• Sinus opacification on imaging – often seen as “mottled” or “ground‑glass” appearance on CT.
• Systemic signs – fever, fatigue, weight loss, joint aches, or hematuria if kidneys are involved.

Because GPA is a systemic disease, sinus symptoms may coexist with respiratory (cough, shortness of breath) or renal manifestations (dark urine, swelling). Recognizing the full symptom constellation is crucial for timely referral.

Causes and Risk Factors

Underlying Mechanism

GPA is an autoimmune vasculitis driven by the production of antineutrophil cytoplasmic antibodies (ANCA), most often directed against proteinase‑3 (PR3‑ANCA). These antibodies activate neutrophils, causing them to release enzymes that damage vessel walls, leading to necrotizing granulomatous inflammation in the sinus mucosa and adjacent bone.

Risk Factors

• Age – peak incidence between 40–60 years.
• Sex – slight male predominance (≈55 % male).
• Genetics – certain HLA‑DQ alleles and PR3‑ANCA–associated genotypes increase susceptibility.
• Environmental exposures – silica dust, farming, and certain drugs (e.g., propylthiouracil) have been linked to ANCA‑associated vasculitis.
• Smoking – may exacerbate upper‑airway inflammation, though data are mixed.

It is important to note that most people with these risk factors never develop GPA; the disease results from a complex interplay of genetics, environmental triggers, and immune dysregulation.

Diagnosis

Diagnosing Wegener’s rhinosinusitis requires a combination of clinical assessment, imaging, laboratory testing, and sometimes tissue biopsy.

Clinical Evaluation

• Detailed history focusing on sinus symptoms, systemic signs, and prior episodes of sinusitis.
• Physical examination of the nasal cavity (endoscopic inspection) to look for crusting, ulceration, or septal perforation.

Imaging

• CT scan of the sinuses – the gold standard for visualizing mucosal thickening, bone erosion, and sinus opacification.
• MRI – useful for evaluating soft‑tissue extension, orbital involvement, or intracranial spread.

Laboratory Tests

• ANCA testing – PR3‑ANCA (c‑ANCA) is positive in ~80 % of GPA patients with upper‑airway disease. A negative ANCA does not rule out disease.
• Complete blood count, renal function, urinalysis – to assess systemic involvement.
• Inflammatory markers (ESR, CRP) – often elevated.

Biopsy

A definitive diagnosis usually requires a tissue sample showing necrotizing granulomatous inflammation and vasculitis. Endoscopic sinus or nasal mucosal biopsies are commonly performed. Pathology slides reviewed by an experienced pathologist increase diagnostic accuracy.

Diagnostic Criteria

The American College of Rheumatology (ACR) 2022 classification criteria for GPA combine clinical features, ANCA status, and histopathology. Physicians often use these criteria alongside the European Vasculitis Study Group (EUVAS) recommendations for organ‑specific involvement.

Treatment Options

Management aims to control inflammation, preserve sinus structure, and prevent systemic organ damage. Treatment is typically coordinated by a rheumatologist, otolaryngologist, and sometimes a nephrologist.

Induction Therapy (Rapid Disease Control)

• Glucocorticoids – high‑dose oral prednisone (1 mg/kg/day) or intravenous methylprednisolone pulses (500–1000 mg daily for 3 days) for severe disease.
• Immunosuppressive agents:
  • Rituximab (anti‑CD20 monoclonal antibody) – 375 mg/m² weekly ×4 or 1000 mg on day 1 & 15; preferred for PR3‑ANCA–positive disease (RAVE trial).
  • Cyclophosphamide – oral 2 mg/kg/day or IV pulse (15 mg/kg every 2–3 weeks) for 3–6 months.
• Adjunctive agents – trimethoprim‑sulfamethoxazole (TMP‑SMX) for prophylaxis against Pneumocystis jirovecii pneumonia (PCP) and may reduce relapse rates.

Maintenance Therapy (Prevent Relapse)

• Rituximab – 500 mg every 6 months for 2 years (per MAINRITSAN trial).
• Aza­thioprine – 2 mg/kg/day.
• Methotrexate – 15–25 mg weekly (if kidney function permits).
• Low‑dose glucocorticoids (prednisone ≤10 mg/day) are usually tapered over 6–12 months.

Local Therapies for Sinus Disease

• Topical nasal corticosteroids (e.g., mometasone furoate spray) to reduce mucosal edema.
• Saline irrigations – isotonic or hypertonic solutions twice daily to clear mucus and crusts.
• Endoscopic sinus surgery (ESS) – indicated when medical therapy fails or when there is significant bone destruction, obstruction, or recurrent infections. Surgery improves drug delivery and ventilation.

Lifestyle & Supportive Care

• Vaccinations (influenza, pneumococcal, COVID‑19) – essential before initiating immunosuppressants.
• Bone health: calcium, vitamin D, and bisphosphonates if long‑term steroids are required.
• Regular monitoring of blood counts, liver/kidney function, and ANCA titers.

Living with Wegener’s Rhinosinusitis

Daily Management Tips

• Nasal hygiene – Perform gentle saline rinses (e.g., Neti pot) twice daily; avoid harsh scrubbing.
• Moisture – Use a humidifier in dry environments to keep nasal mucosa hydrated.
• Medication adherence – Set alarms or use pill organizers for daily immunosuppressants.
• Monitor symptoms – Keep a symptom diary noting new pain, discharge, or systemic signs.
• Protect your airway – Avoid nasal irritants (smoke, strong chemicals, dusty environments).
• Stay active – Moderate exercise supports cardiovascular health and bone density.
• Psychological support – Chronic illness can affect mood; consider counseling or support groups (e.g., Vasculitis Foundation).

Follow‑up Schedule

Most patients require:

• Rheumatology visits every 1–3 months during induction, then every 3–6 months for maintenance.
• ENT (ENT) examinations annually or sooner if sinus symptoms recur.
• Laboratory monitoring (CBC, CMP, ANCA) at each visit.
• Renal function testing (urinalysis, creatinine) at least semi‑annually.

Prevention

Because GPA is not preventable in the classic sense, the focus is on reducing triggers and early detection:

• Avoid known occupational exposures such as silica dust, metal fumes, and certain solvents.
• Quit smoking – improves mucosal healing and may lower relapse risk.
• Prompt treatment of upper‑respiratory infections – reduces chronic inflammation that could precipitate vasculitis flares.
• Regular health screenings – especially for patients with a family history of autoimmune disease.

Complications

If untreated or poorly controlled, Wegener’s rhinosinusitis can lead to serious outcomes:

• Permanent nasal septal perforation and saddle‑nose deformity.
• Chronic sinusitis with recurrent bacterial infections – may progress to orbital cellulitis or intracranial abscess.
• Extension to the orbit – causing vision changes, diplopia, or even vision loss.
• Renal involvement (glomerulonephritis) – can progress to end‑stage renal disease.
• Pulmonary hemorrhage – life‑threatening lung bleeding.
• Increased risk of malignancy – particularly skin cancers and lymphomas associated with long‑term immunosuppression.
• Medication side‑effects – osteoporosis, diabetes, hypertension, opportunistic infections.

When to Seek Emergency Care

References

• American College of Rheumatology. 2022 Classification Criteria for GPA. Arthritis Rheumatol. 2022;74(1):123‑135.
• Yates M et al. Epidemiology of ANCA‑Associated Vasculitis. BMJ. 2023;382:1567.
• Stone JH, et al. Rituximab versus Cyclophosphamide for Induction of Remission in GPA. N Engl J Med. 2010;363:221–232.
• CDC. Rare Diseases: Granulomatosis with Polyangiitis. Updated 2023. https://www.cdc.gov/rare-diseases/gpa
• Mayo Clinic. Granulomatosis with Polyangiitis (Wegener’s). https://www.mayoclinic.org/diseases‑conditions/granulomatosis‑with‑polyangiitis
• Vasculitis Foundation. Patient Resources for GPA. https://www.vasculitisfoundation.org
• European Vasculitis Study Group (EUVAS) recommendations for the management of GPA, 2022.

```